Overview
Venlafaxine Augmentation in Treatment Resistant Depression
Status:
Completed
Completed
Trial end date:
2014-08-01
2014-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is an assessment of the efficacy of venlafaxine-HCL augmentation with the neuroleptic quetiapine in treatment resistant depression.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Max-Planck-Institute of PsychiatryTreatments:
Quetiapine Fumarate
Venlafaxine Hydrochloride
Criteria
Inclusion Criteria:- Female and male inpatients with a major depressive disorder without psychotic features
or with a depressive episode within a bipolar I or II disorder without psychotic
features
- Ages between 20 and 70 years
- Total score greater than 18 on the Hamilton Depression Rating Scale
- Documentation of at least one ineffective antidepressant drug trial under adequate
dosage for at least 6 weeks in the current episode
Exclusion Criteria:
- Other psychiatric axis I disorders than those mentioned as Inclusion criteria
- Acute suicidality (Item 3 of the Hamilton Depression Rating Scale greater than 2)
- Drug or alcohol addiction
- Patients with severe hepatic, cardiovascular, neurologic, metabolic or malignant
disorders
- Documentation or report of a previous ineffective treatment trial with venlafaxine,
lamotrigine or quetiapine
- Functional kidney disorders
- Untreated hypertension
- Acute treatment with thyroid hormone (less than 3 months)
- Pregnant or nursing patients
- Women of childbearing age without effective contraception